The global leukapheresis market size was estimated at USD 211.3 million in 2024 and is projected to reach USD 394.1 million by 2030, growing at a CAGR of 11.05% from 2025 to 2030. The market’s growth is primarily driven by the rising prevalence of blood disorders and autoimmune diseases, ongoing technological advancements in leukapheresis procedures, and the increasing demand for personalized medicine.
In addition, growing investments in research and development are further supporting market expansion. The increasing incidence of blood disorders such as leukemia, lymphoma, and autoimmune diseases—including rheumatoid arthritis and multiple sclerosis—is a key factor propelling the demand for leukapheresis treatments.
For example, according to the Leukemia & Lymphoma Society, approximately 184,720 people in the U.S. were expected to receive a diagnosis of leukemia, lymphoma, or myeloma in 2023. Additionally, a May 2023 study published in The Lancet, involving 22 million people, reported that autoimmune disorders affect 1 in 10 individuals. The study highlighted the influence of socioeconomic, seasonal, and regional factors on disease prevalence and provided insights into the causes of autoimmune conditions such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. These statistics underscore the significant medical need for leukapheresis procedures, driving demand for these treatments throughout the forecast period.
Key Market Trends & Insights:
• In 2024, North America dominated the global leukapheresis market, holding the largest revenue share of 36.86%. The region’s leadership is driven by advanced healthcare infrastructure, high adoption of innovative medical technologies, substantial R&D investments, and the presence of key market players that support the widespread use of leukapheresis procedures.
• Within North America, the U.S. leukapheresis market is expected to witness the fastest growth rate over the forecast period. This rapid expansion can be attributed to increasing prevalence of blood disorders and autoimmune diseases, growing awareness among healthcare providers, and strong government and private investments in advanced medical technologies and research initiatives.
• By product type, the leukapheresis devices segment led the market in 2024, accounting for the largest revenue share of 69.12%. These devices are critical for performing leukapheresis procedures efficiently and safely, enabling precise separation and collection of blood components for therapeutic and research purposes.
• By application, the research segment dominated the market with a revenue share of 77.65% in 2024. The high adoption in research settings is driven by the need for advanced studies on blood disorders, immune response mechanisms, and development of personalized medicine, which require reliable and high-quality leukapheresis products.
• In terms of end-use, the hospitals and clinics segment led the market with a revenue share of 64.25% in 2024. Hospitals and clinics are the primary facilities performing leukapheresis procedures, benefiting from well-equipped infrastructure, trained medical personnel, and access to a large patient population, making them the dominant end-use segment for these products.
Order a free sample PDF of the Leukapheresis Market Intelligence Study, published by Grand View Research.
Market Size & Forecast:
• 2024 Market Size: USD 211.3 Million
• 2030 Projected Market Size: USD 394.1 Million
• CAGR (2025-2030): 11.05%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market
Key Companies & Market Share Insights:
Key players operating in the leukapheresis industry are actively implementing a range of strategies to strengthen their market presence and expand the reach of their products and services. These companies are focusing on initiatives such as geographic expansion, entering new markets, and increasing production capacities to meet growing demand. In addition, strategic partnerships, collaborations with research institutions, and alliances with healthcare providers are being pursued to enhance product distribution, improve service delivery, and drive adoption of leukapheresis technologies. Such initiatives not only bolster the competitive positioning of these companies but also contribute significantly to overall market growth by facilitating wider accessibility and promoting awareness of leukapheresis solutions across different regions and medical applications.
Key Players
• Charles River Laboratories International, Inc.
• Adacyte Therapeutics
• AllCells, LLC
• Asahi Kasei Medical
• Haemonetics Corporation
• Macopharma
• Cerus Corporation
• SB-Kawasumi Laboratories, Inc.
• StemExpress, LLC.
• Haemonetics Corporation
• Caltag Medsystems Limited
• Lonza Group AG
• ZenBio
• Terumo BCT, Inc.
• Macopharma SA
• Miltenyi Biotec
• Fresenius SE & Co. KGaA
• Guangzhou Daji Medical Science
• MEDICA S.p.A
• PuriBlood Medical Co. Ltd.
• Beijing ZKSK Technology Co. Ltd.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
The global leukapheresis market is poised for substantial growth, driven by the rising prevalence of blood disorders and autoimmune diseases, technological advancements in leukapheresis procedures, and the increasing demand for personalized medicine. North America currently leads the market, with the U.S. expected to experience the fastest growth. Product-wise, leukapheresis devices hold the largest market share, while research applications dominate in terms of application. Hospitals and clinics are the primary end-users of leukapheresis products. Key players in the industry are focusing on strategic initiatives such as geographic expansion and partnerships to enhance their market presence and product reach.
